Resiliva (Resmetirom) is a generic version of Rezdiffra which is a thyroid hormone receptor beta (THR-β) agonist. By targeting THR-β, it promotes lipid metabolism in the liver, reducing hepatic fat accumulation and improving lipid profiles. It is the first and only FDA-approved treatment for NASH with liver scarring, along with diet and exercise.